Senate hearing urges tighter protections for reproductive and gender‑affirming care under 2022 ‘shield law’

At a public hearing, the Massachusetts Senate Committee on Steering and Policy heard detailed testimony urging lawmakers to tighten and clarify the 2022 “shield law” that protects reproductive and gender‑affirming health care in the Commonwealth.

The hearing drew testimony from the attorney general’s office, civil‑liberties groups, medical societies, provider organizations and advocacy groups, all of whom recommended targeted changes: extend noncooperation rules to all state and local agencies, give the attorney general explicit enforcement authority, segregate sensitive data in electronic medical records, exclude certain medications from the state prescription monitoring program and allow dispensing providers to appear on prescription labels as a practice name rather than an individual clinician.

The protections matter because, speakers said, hostile federal actors and out‑of‑state officials are increasingly using civil and criminal tools to pursue providers and patients. “We cannot and should not wait to see how that reconciliation bill fares in the US Senate,” Senate Chair Cindy Friedman said in opening remarks, pointing to recent federal and out‑of‑state actions that advocates say have increased risks for providers and patients.

Allison Slater, director of Attorney General Andrea Campbell’s Reproductive Justice Unit, told the committee that Massachusetts’ shield law was “nation leading” when passed in 2022 but that developments since then exposed gaps. Slater recommended several statutory changes, including extending the law’s bar on law‑enforcement cooperation to all state and local agencies and employees; giving the attorney general explicit authority to enforce the shield law; protecting electronic medical records and public‑health surveillance data from out‑of‑state access; excluding reproductive and gender‑affirming medications from the state prescription monitoring program; allowing pharmacies to display a practice name on dispensed medication labels instead of an individual clinician’s name; and adopting a state analogue to EMTALA to require hospitals to provide emergency stabilization care, including emergency abortion care.

Civil‑liberties and provider groups amplified those proposals. Gavi Wolf of the ACLU of Massachusetts urged lawmakers to extend the law’s information‑sharing limits beyond law enforcement to touchpoints across state government, including the Department of Public Health, and to vest public‑health specialists with authority to retain only data necessary for public‑health purposes. Polly Crozier of GLAD (GLBTQ Legal Advocates and Defenders) highlighted barriers transgender people face for basic legal steps such as name changes and urged protections for attorneys, nonprofit legal organizations and providers from discipline or other sanctions for working on gender‑affirming care.

Physicians and medical groups described clinical and technical vulnerabilities. Dr. Megan Evans, an OB‑GYN testifying for the Massachusetts section of the American College of Obstetricians and Gynecologists, and Dr. Chloe Zara, a maternal‑fetal medicine specialist testifying for the Society for Maternal Fetal Medicine, warned that common hospital electronic medical records (Epic, cited repeatedly) can allow remote access across systems, exposing notes, medication orders or procedure records that could be used against patients or clinicians in hostile jurisdictions. Dr. James Wang, representing the Massachusetts Medical Society, urged exclusion of gender‑affirming and reproductive prescriptions from the state Prescription Monitoring Program and asked the legislature to permit practice‑level labeling to protect individual clinicians from harassment or legal targeting.

Provider organizations and nonprofit clinic operators described practical harms already encountered. Julia Kehoe, CEO of Health Imperatives, said her organization operates seven reproductive clinics across southeastern Massachusetts and serves roughly 23,000 people, and testified that commercial insurers and malpractice underwriters have reacted to national hostility by restricting or charging much higher premiums for coverage tied to abortion or gender‑affirming care. Kehoe said one long‑time insurer would not rate her organization’s malpractice for abortion services, and that separate quotes for abortion coverage ranged from $250,000 to $500,000. She urged statutory clarification to prevent insurance discrimination against providers.

Grant Drain, chief of staff at Trans Health, and other advocates described fear among patients, parents and providers — including concern about license loss, civil suits and criminal prosecutions in other states — and urged lawmakers to close perceived gaps in the current statute. A citizen speaker from a reproductive‑justice task force urged reconsideration of Massachusetts’ post‑24‑week abortion restrictions, calling them a barrier for vulnerable patients; that position was recorded as public comment rather than part of committee policy recommendations.

Committee members pressed witnesses on technical tradeoffs. Several senators raised questions about unintended consequences of restricting data — for example, the importance of information for clinical research, care coordination and emergency treatment — and witnesses and clinicians recommended a mix of structural safeguards in electronic health records and stronger patient control mechanisms (specialized consent flags and segmented records) rather than blanket blocks. Several witnesses suggested the committee consult electronic record vendors and major hospital systems to develop practicable technical standards.

The attorney general’s office said it would follow up with more detail on the enforcement mechanisms it seeks, and committee members suggested convening technical meetings with EMR vendors and major health systems. The committee’s chair reiterated that the testimony would inform draft legislation and that written comment would be accepted as the committee proceeds. The hearing concluded after a motion to close was moved and seconded.

The committee’s next step, officials said, will be to use testimony and written submissions to craft statutory language and solicit public comment before filing and advancing any bill.